Clinical trial
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent…
NCT00093496 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00093496 |
|---|---|
| Title | Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer |
| Official title | A Phase II Trial Of Gemcitabine in Combination With 17-Allylaminogeldamycin (17-AAG) In Advanced Epithelial Ovarian And Primary Peritoneal Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride, tanespimycin |
| Enrollment | 29 |
| Start date | Oct 1, 2007 |
| Primary completion | Apr 1, 2010 |
| Completion | Mar 1, 2012 |
| First posted | Oct 8, 2004 |
| Last update posted | May 20, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: